Patent: 5,385,839
✉ Email this page to a colleague
Summary for Patent: 5,385,839
Title: | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter regulatory DNA sequence |
Abstract: | The cloning of a eucaryotic promoter-regulatory region that functions preferentially in human cells is disclosed. The invention is exemplified by the cloning of a section of the human cytomegalovirus genome comprising a DNA sequence with regulatory and promoter signals and an initiation site for RNA synthesis. The fragment, termed the human cytomegalovirus (HCMV) promoter-regulatory sequence, was obtained from purified HCMV DNA. |
Inventor(s): | Stinski; Mark F. (Iowa City, IA) |
Assignee: | University of Iowa Research Foundation (Iowa City, IA) |
Application Number: | 07/900,056 |
Patent Claims: | see list of patent claims |
Details for Patent 5,385,839
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | November 23, 2004 | ⤷ Sign Up | 2005-01-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,385,839
Country | Patent Number | Estimated Expiration |
---|---|---|
United States of America | 5168062 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |